Salarius Pharmaceuticals Inc
NASDAQ:SLRX

Watchlist Manager
Salarius Pharmaceuticals Inc Logo
Salarius Pharmaceuticals Inc
NASDAQ:SLRX
Watchlist
Price: 0.535 USD -17.94%
Market Cap: 3.1m USD

Salarius Pharmaceuticals Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Salarius Pharmaceuticals Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Salarius Pharmaceuticals Inc
NASDAQ:SLRX
Net Income (Common)
-$5m
CAGR 3-Years
45%
CAGR 5-Years
8%
CAGR 10-Years
15%
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$2.3B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$8.1B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

Salarius Pharmaceuticals Inc
Glance View

Market Cap
3.1m USD
Industry
Biotechnology

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The company is headquartered in Houston, Texas and currently employs 16 full-time employees. The company went IPO on 2015-01-29. In addition, the Company is also developing treatments for cancers caused by dysregulated gene expression. The firm is developing two classes of drugs that address gene dysregulation: epigenetic drugs and targeted protein degraders. The Company’s technologies have the potential to work in both liquid and solid tumors. The Company’s pipeline consists of two compounds: seclidemstat (SP-2577), which is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (LSD1); SP-2577 uses a reversible mechanism to inhibit LSD1’s enzymatic and scaffolding properties and thereby treat and prevent cancer progression, and SP-3164, which is a cereblon binding molecular glue and has a development path in hematological cancer and potential in solid tumors.

SLRX Intrinsic Value
Not Available

See Also

What is Salarius Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-5m USD

Based on the financial report for Sep 30, 2025, Salarius Pharmaceuticals Inc's Net Income (Common) amounts to -5m USD.

What is Salarius Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
15%

Over the last year, the Net Income (Common) growth was 0%. The average annual Net Income (Common) growth rates for Salarius Pharmaceuticals Inc have been 45% over the past three years , 8% over the past five years , and 15% over the past ten years .

Back to Top